Benefits of AnaViRx compounds against Influenza and other viruses

One of AnaViRx early lead candidates (AVX11001/Anavir) has shown broad activity against many flu strains. As shown in the figure below, AVX11001 shows dose-dependent activity against seasonal flu (H3N2), swine flu (H1N1), avian flu (H5N1) as well as Flu type B, H9N2, H7N3 and H5N2. The effects against the viruses are dose dependent with medium-high doses resulting in .>2.5 logs reduction in viral titers in cells in vitro.



[Home] [Antiviral Platform] [Influenza] [Flavivirus Infections] [Benefits of AnaViRx compounds] [Pipeline] [Careers] [Contact Us] [Investors]